Yield of prostate cancer screening at a community based clinic in Saudi Arabia

References

1. ↵
   1. Siegel RL,
   2. Miller KD,
   3. Jemal A

   (2016) Cancer statistics 2016. CA Cancer J Clin 66:7–30.

   OpenUrlCrossRefPubMedGoogle Scholar
2. ↵
   1. Chinese Prostate Cancer Consortium,
   2. Chen R,
   3. Ren S,
   4. Yiu MK,
   5. Fai NC,
   6. Cheng WS,
   7. et al.

   (2014) Prostate cancer in Asia:a collaborative report. Asian J Urol 1:15–29.

   OpenUrlGoogle Scholar
3. ↵
   1. Al-Zahrani AS,
   2. Al-Mutlaq HM,
   3. Radwi AN,
   4. Bazarbashi SM

   (2017) Cancer incidence reports Saudi Arabia 2014 (Saudi Health Council, Riyadh), p 83.

   Google Scholar
4. ↵
   1. Alghamidi IG,
   2. Hussain II,
   3. Alghamdi MS,
   4. El-Sheemy MA

   (2014) The incidence rate of prostate cancer in Saudi Arabia:an observational descriptive epidemiological analysis of data from the Saudi Cancer Registry 2001-2008. Hematol Oncol Stem Cell Ther 7:18–26.

   OpenUrlGoogle Scholar
5. ↵
   1. Rabah DM,
   2. Arafa MA

   (2010) Prostate cancer screening in a Saudi population:an explanatory trial study. Prostate Cancer Prostatic Dis 13:191–194.

   OpenUrlPubMedGoogle Scholar
6. ↵
   1. Carter HB,
   2. Albertsen PC,
   3. Barry MJ,
   4. Etzioni R,
   5. Freedland SJ,
   6. Greene KL,
   7. et al.

   (2013) Early detection of prostate cancer:AUA guideline. J Urol 190:419–426.

   OpenUrlCrossRefPubMedWeb of ScienceGoogle Scholar
7. ↵
   1. Moyer VA,
   2. U.S. Preventive Services Task Force

   (2012) Screening for prostate cancer:US Preventive Services Task Force recommendation statement. Ann Intern Med 157:120–134.

   OpenUrlCrossRefPubMedWeb of ScienceGoogle Scholar
8. ↵
   1. Bell N,
   2. Gorber SC,
   3. Shane A,
   4. Joffres M,
   5. Singh H,
   6. Dickinson J,
   7. et al.

   (2014) Recommendations on screening for prostate cancer with the prostate-specific antigen test. CMAJ 186:1225–1234.

   OpenUrlFREE Full TextGoogle Scholar
9. ↵
   1. Mottet N,
   2. Bellmunt J,
   3. Bolla M,
   4. Briers E,
   5. Cumberbatch MG,
   6. De Santis M,
   7. et al.

   (2017) EAU-ESTRO-SIOG guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent. Eur Urol 71:618–629.

   OpenUrlPubMedGoogle Scholar
10. ↵
    1. Segi M,
    2. Kurihara M,
    3. Tsukahara Y

    (1966) Cancer Mortality for Selected Sites in 24 Countries: No. 4 (1962-63) (Tohoku University, School of Medicine. Department of Public Health).

    Google Scholar
11. ↵
    1. Saudi Census

    General Authority for Statistics, Updated 2019, Available from: https://www.stats.gov.sa/ar/13. Accessed 2018 February 16th.

    Google Scholar
12. ↵
    1. World Cancer Research Fund

    American Institute for Cancer Research. Age standardized incidence rate of prostate cancer, Updated 2007, Available from: http://www.wcrf.org/int/cancer-facts-figures/data-specific-cancers/prostate-cancer-statistics. Accessed 2017 September 9th.

    Google Scholar
13. ↵
    1. Walter LC,
    2. Fung KZ,
    3. Kirby KA,
    4. Shi Y,
    5. Espaldon R,
    6. O'Brien S,
    7. et al.

    (2013) Five-year downstream outcomes following prostate-specific antigen screening in older men. JAMA Intern Med 173:866–873.

    OpenUrlGoogle Scholar
14. ↵
    1. Hoffman RM,
    2. Gilliland FD,
    3. Adams-Cameron M,
    4. Hunt WC,
    5. Key CR

    (2002) Prostate-specific antigen testing accuracy in community practice. BMC Fam Pract 3:19.

    OpenUrlCrossRefPubMedGoogle Scholar
15. ↵
    1. Zahir ST,
    2. Nazemian MR,
    3. Zand S,
    4. Zare S

    (2014) Survival of patients with prostate cancer in Yazd, Iran. Asian Pac J Cancer Prev 15:883–886.

    OpenUrlGoogle Scholar
16. ↵
    1. Carter H. Ballentine,
    2. Jonathan I. Epstein,
    3. Alan W. Partin

    (1999) Influence of age and prostate-specific antigen on the chance of curable prostate cancer among men with nonpalpable disease. Urology 53:126–130.

    OpenUrlCrossRefPubMedWeb of ScienceGoogle Scholar
17. ↵
    1. Pourmand G,
    2. Salem S,
    3. Mehrsai A,
    4. Lotfi M,
    5. Amirzargar MA,
    6. Mazdak H,
    7. et al.

    (2007) The risk factors of prostate cancer:a multicetric case-control study in Iran. Asian Pac J Cancer Prev 8:422–428.

    OpenUrlPubMedWeb of ScienceGoogle Scholar
18. ↵
    1. O'Malley RL,
    2. Taneja SS

    (2006) Obesity and prostate cancer. Can J Urol 13(Suppl 2):11–17.

    OpenUrlPubMedGoogle Scholar
19. ↵
    1. Yu XQ,
    2. Luo Q,
    3. Smith DP,
    4. Clements MS,
    5. O'Connell DL

    (2015) Prostate cancer prevalence in New South Wales Australia:A population-based study. Cancer Epidemiol 39:29–36.

    OpenUrlGoogle Scholar
20. 1. Romero FR,
    2. Romero AW,
    3. Almeida RM,
    4. Tambara Filho R

    (2012) The prevalence of prostate cancer in Brazil is higher in Black men than in White men:systematic review and meta-analysis. Int Braz J Urol 38:440–447.

    OpenUrlPubMedGoogle Scholar
21. 1. Safarinejad MR

    (2006) Population-based screening for prostate cancer by measuring free and total serum prostate-specific antigen in Iran. Ann Oncol 17:1166–1171.

    OpenUrlCrossRefPubMedGoogle Scholar
22. ↵
    1. Çeber E,
    2. Şimşir A,
    3. Umar DÇ,
    4. Karababa AO,
    5. Günaydın G,
    6. Çal Ç,
    7. et al.

    (2010) Prevalence of prostate cancer among men aged 40+living in Osman Gazi health care district. Asian Pac J Cancer Prev 11:473–478.

    OpenUrlPubMedGoogle Scholar